Case Closed: Migraine Treatment Updates

Track 2: Challenging Cases
Saturday, February 8, 2020 - 2:00-3:00 pm
UAN: 0107-9999-20-013-L01-P
0.1 CEU/1 hr
In recent years, the treatment of migraines has evolved with approval of the first medication class
specific to migraines, the Calcitonin Gene-Related Peptide (CGRP) inhibitors. Previously, clinicians were limited to borrowing medications from other indications, such as antidepressants and antihypertensives, to treat patients with migraines. This course provides a case-based approach to discuss the role of the CGRP inhibitors in the context of migraine management, as well as other strategies for migraine prevention and treatment.      

Learning Objectives
Upon successful completion of this knowledge-based CPE activity, participants should be able to:
1. Differentiate episodic and chronic migraine by listing criteria for diagnosis of each type, including concomitant symptoms and frequency of headaches.
2. Determine appropriateness of medications for migraine prevention and develop a treatment plan for patient cases.
3. Explain the mechanism and place in therapy for the Calcitonin Gene-related Peptide (CGRP) inhibitors.
4. Define medication overuse in the context of migraine management.
5. List evidence-based abortive therapies for migraine.

Natalie Roy
Natalie Roy, PharmD

MTM Pharmacist
MHealth Fairview
Minneapolis, MN